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Abstract
Background: Influenza A virus (IVA) exploits diverse cellular gene products to support its
replication in the host. The significance of the regulatory (β) subunit of casein kinase 2 (CK2β) in
various cellular mechanisms is well established, but less is known about its potential role in IVA
replication. We studied the role of CK2β in IVA-infected A549 human epithelial lung cells.
Results: Activation of CK2β was observed in A549 cells during virus binding and internalization
but appeared to be constrained as replication began. We used small interfering RNAs (siRNAs)
targeting CK2β mRNA to silence CK2β protein expression in A549 cells without affecting
expression of the CK2α subunit. CK2β gene silencing led to increased virus titers, consistent with
the inhibition of CK2β during IVA replication. Notably, virus titers increased significantly when
CK2β siRNA-transfected cells were inoculated at a lower multiplicity of infection. Virus titers also
increased in cells treated with a specific CK2 inhibitor but decreased in cells treated with a CK2β
stimulator. CK2β absence did not impair nuclear export of viral ribonucleoprotein complexes (6 h
and 8 h after inoculation) or viral polymerase activity (analyzed in a minigenome system). The
enhancement of virus titers by CK2β siRNA reflects increased cell susceptibility to influenza virus
infection resulting in accelerated virus entry and higher viral protein content.
Conclusion: This study demonstrates the role of cellular CK2β protein in the viral biology. Our
results are the first to demonstrate a functional link between siRNA-mediated inhibition of the
CK2β protein and regulation of influenza A virus replication in infected cells. Overall, the data
suggest that expression and activation of CK2β inhibits influenza virus replication by regulating the
virus entry process and viral protein synthesis.
Background
Protein kinase CK2 is a pleiotropic, proliferation-associ-
ated, highly conserved and constitutively active Ser/Thr
protein kinase found in the nucleus and cytoplasm of
most cells [1-5]. CK2 is a tetramer comprising 2 functional
catalytic subunits (α,α', or both) and 2 regulatory β subu-
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erotetramer [2,6-8]. CK2 is involved in many signal
transduction pathways and in negative regulation of
apoptosis [8-10]. It appears to play crucial roles in cell
cycle and growth control via phosphorylation of several
important substrates, including p53 [11], Cdc2 [12], and
BRCA1 [13]. Mice lacking CK2α have lethal cardiac neural
tube structural defects, highlighting the specific role of
CK2α in the development of these organs [14]. Male
CK2α'-knockout mice have defective spermatogenesis
and are sterile [15]. CK2β is essential for cell viability in
mice and is therefore required during early embryonic
development [6].
The β-subunit of CK2 is trifunctional: (1) it stabilizes the
heterotetrameric holoenzyme [16,17]; (2) it increases
enzyme activity [18-20]; and (3) it determines substrate
specificity [17,21]. Structure-function studies in vitro sup-
port a direct link between CK2 activity and the phosphor-
ylation status of the β-subunit [22,23]. Using mass
spectrometry analysis, Arrigoni et al. recently identified
144 different cellular proteins that interact with CK2β,
10% of which are involved in signaling pathways [24].
Type A influenza virus (IVA), belonging to the family
Orthomyxoviridae, is highly contagious and causes devas-
tating outbreaks in humans and several animal species. Its
genome comprises 8 single-strand, negative-sense RNA
molecules that encode as many as 11 viral proteins. These
RNA segments are associated with nucleoproteins (NPs)
and 3 RNA-dependent RNA polymerase subunits (PB1,
PB2, and PA) to form viral ribonucleoprotein (RNP) com-
plexes, which are the minimal infectious viral structures.
The viral genome is replicated and transcribed in the host
cell nucleus, requiring bidirectional transport through the
nuclear membrane via nuclear pore complexes [25].
Because of the limited coding capacity of their genome,
IVAs extensively employ host cellular mechanisms,
including many different signaling pathways, to promote
their replication [26-29].
IVAs appear to have acquired the capacity to either repress
or exploit cellular responses that are upregulated during
viral infection. For example, expression of the β-isoform
of the protein kinase C superfamily (PKCβII) and activa-
tion of the Raf/MEK/ERK signal cascade, appears to pro-
mote IVA replication. PKCβII is a specific regulator of
influenza virus entry into late endosomes [30,31],
whereas phosphorylation of ERK is required for efficient
nuclear export of viral RNP complexes [29,32]. Further,
inhibition of PKC by the protein kinase inhibitor H7
alters the phosphorylation pattern of the NP protein [33]
and causes retention of the late viral mRNAs in the
nucleus [34]. In addition, activation of the nuclear factor
NF-κB in response to IVA infection is partially suppressed
by the viral NS1 protein, presumably to prevent excessive
expression of interferon β (IFNβ), while at the same time
the virus appears to use the remaining NF-κB activity for
apoptosis-related and virus-supporting processes [26,35].
Sanz-Ezquerro et al. [36] demonstrated that the PA
polymerase protein of IVA is phosphorylated at serine and
threonine residues in cultured cells. Moreover, PA protein
is a substrate of CK2α in vitro, suggesting that this kinase
is involved in covalent posttranslational modification of
PA. Other viruses have been shown to interact with this
cellular kinase as well. CK2 phosphorylation of the P pro-
tein (subunit of the RNA-dependent RNA polymerase
complex) of vesicular stomatitis virus is essential for its
activity in viral transcription [37,38], and CK2 phosphor-
ylation sites are found in the P protein of measles virus
[39].
Although the significance of CK2β in various cellular
mechanisms is well established, less is known about its
role in IVA replication. We studied the involvement of
CK2β at different stages of viral infection in human epi-
thelial lung A549 cells. We used small interfering RNAs
(siRNAs) specifically targeting CK2β mRNA to diminish
CK2β protein expression and studied the effect on virus
titers, virus internalization, viral protein synthesis, nuclear
export of viral RNP complexes, and viral polymerase activ-
ity.
Results
CK2β is not activated during influenza virus replication
To demonstrate that CK2β can be activated in A549 cells,
we assessed CK2β activation at different time points after
stimulation with spermine (a polyamine that regulates
CK2 activity through direct interaction with the β subunit
of the holoenzyme [40]) or with the broad kinase activa-
tor 12-O-tetradecanoyl-phorbol-13-acetate (TPA). In
spermine-stimulated cells, CK2β activation was increased
at 2 h and 4 h but had returned to the basal level at 6 h
and 8 h (Figure 1a, left). TPA treatment caused stronger
kinase activation than did spermine, as compared to the
respective controls. TPA-induced CK2β activation reached
its highest level at 4 h and had progressively decreased at
6 h and 8 h (Figure 1a, right). These results show that
CK2β can indeed be activated in the cell line used for this
study.
To assess whether CK2β is activated by influenza virus, we
incubated A549 cells with medium containing the human
A/Puerto Rico/8/34 influenza virus (multiplicity of infec-
tion [MOI] = 5) for 1 h at 37°C and then analyzed CK2β
activation at different time points by using an antibody
that detects serine phosphorylation at position 209 of
CK2β. CK2β activation in uninoculated cells was assigned
a value of 100% (baseline control). CK2β activation didPage 2 of 15
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point during hours 2 to 20 after inoculation (Figure 1b),
suggesting that CK2β is not activated during influenza
virus replication.
We next assessed CK2β activation during the 1-h inocula-
tion period, when virus binds to cells and is internalized.
Cells were incubated with virus-containing medium (MOI
= 5) at 4°C for 20 min. The medium was then replaced
with pre-warmed medium and cells were incubated at
37°C. CK2β activation was analyzed 0, 30, 45, and 60
min after start of inoculation period. At 45 min and 60
min after infection, CK2β activation was approximately
65% and 80%, respectively, greater than that in control
cells (Figure 1c). Therefore, CK2β activation is upregu-
lated very early in the viral life cycle and is inhibited when
virus replication starts.
Timing of CK2β activationF gure 1
Timing of CK2β activation. (a) A549 cells were treated with either spermine (300 μM) or TPA (200 ng/ml) and further 
incubated for the times as indicated. (b) A549 cells were incubated with virus-containing medium (MOI = 5) at 37°C for 1 h, 
medium was replaced, and cells were further incubated at 37°C for the times as indicated. (c) A549 cells were incubated with 
virus-containing medium (MOI = 5) at 4°C for 20 min and then at 37°C for the times as indicated. CK2β activation was 
assessed at the indicated time points by Western blot with polyclonal rabbit anti-phosphorylated CK2β (P-CK2β). Bands in 
three independent experiments were quantified, and relative CK2β activation (black bars) was calculated and normalized to 
the loading control (anti-CK2β mAb). White bars represent uninoculated cells.Page 3 of 15
(page number not for citation purposes)
Journal of Molecular Signaling 2008, 3:13 http://www.jmolecularsignaling.com/content/3/1/13Inhibition of CK2β expression increases influenza virus 
titers
To evaluate the effect of CK2β on IVA replication, we
silenced CK2β expression in A549 cells by using a gene-
specific siRNA. To ensure that the amount of siRNA
duplex used did not negatively influence cell viability, we
first performed a cell proliferation assay 24 h, 48 h, and 72
h post-transfection (p.t.). CK2β siRNA did not reduce the
number of viable cells or affect cell morphology, as com-
pared to those of control cells, at any time point (data not
shown), suggesting that the amount of siRNA used is not
toxic to the cells.
Total amount of the CK2β protein was assayed 24 h, 48 h,
and 72 h p.t. by Western blot analysis. In cells transfected
with CK2β siRNA, CK2β expression was substantially less
than that in control-transfected cells at 24 h p.t. and was
almost completely absent at 48 h p.t. (Figure 2a), demon-
strating the efficiency of this gene-specific siRNA. The
amount of CK2β protein started to increase again at 72 h
p.t. (Figure 2a), indicating that siRNA-mediated inhibi-
tion of CK2β gene expression is transient. Additionally, to
determine whether CK2β gene silencing negatively affects
expression of the α-subunit of CK2, we assayed CK2α pro-
tein levels at the same 3 time points. CK2α expression was
not reduced in CK2β siRNA-transfected cells at 24 h, 48 h,
or 72 h p.t. (Figure 2b). Because CK2β expression was
most significantly reduced 48 h p.t., cells were inoculated
with virus 48 h p.t. and further incubated for 24 h. At first,
we used a relatively high MOI of 5, as A549 cells are less
Expression of CK2β proteinFigure 2
Expression of CK2β protein. A549 cells were transfected with either control or CK2β siRNA. (a) Total amount of CK2β 
protein detected at 24 h, 48 h, and 72 h post-transfection (p.t.) by Western blot analysis with a mAb specific for the β-subunit 
of CK2. Loading was controlled with a mAb against β-actin. (b) Total CK2α protein detected 24 h, 48 h, and 72 h after trans-
fection with CK2β siRNA.Page 4 of 15
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lines such as MDCK cells. It is noteworthy that most of the
cells remained viable after a 24-h inoculation at this MOI.
Virus titers in the cell supernatants differed substantially
24 h post-inoculation (p.i.). The mean virus titer in CK2β
siRNA-transfected cells was 3 times that in control siRNA-
transfected cells (Figure 3a). The difference in virus titers
was more pronounced when cells were inoculated with a
very low virus dose (MOI = 0.1 and 0.001). At MOI = 0.1,
the mean virus titer was approximately 5 times as high in
siRNA-mediated silencing of CK2β increases virus titersFigure 3
siRNA-mediated silencing of CK2β increases virus titers. (a) A549 cells were transfected with either control (white 
bars) or CK2β (black bars) siRNA for 48 h, then infected at an MOI of 5, 0.1, or 0.001 and incubated for 24 h. Virus in cell 
supernatants was titrated in MDCK cells. (b) A549 cells were inoculated with virus (MOI = 5) and were either left untreated 
(white bars) or treated with the CK2 inhibitor DMAT or the activator spermine (black bars). Virus in cell supernatants was 
titrated at 24 h p.i.. Mean virus titers ± SE from 3 independent experiments are given as a percentage of the control mean and 
as PFU/ml. * P < 0.05 and **P < 0.005 between the indicated groups.Page 5 of 15
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transfected cells (Figure 3a). At MOI = 0.001, the differ-
ence exceeded 1 log10 (Figure 3a).
We next confirmed that CK2β activity influences the out-
come of viral infection. To assess the effect of CK2 inhibi-
tion, we incubated cells with 5 μM 2-dimethylamino-
4,5,6,7-tetrabromo-1H-benzimidazole (DMAT, a potent
and specific CK2 inhibitor [41]) or with solvent (DMSO)
before and during virus inoculation (MOI = 5). To deter-
mine the effect of CK2β activation, we treated cells with
300 μM spermine or with H2O before and during virus
inoculation. At 24 h p.i., the mean virus titer in DMAT-
treated cells increased as compared to controls (Figure
3b). Conversely, cells treated with the CK2β activator
spermine had a mean virus titer approximately half that of
the control titer at 24 h p.i. (Figure 3b). These results again
suggest that activation of CK2β is inconsistent with effi-
cient virus replication.
Inhibition of CK2β expression accelerates influenza virus 
internalization
Having shown that 1) CK2β activation is inhibited during
IVA replication and 2) CK2β silencing results in increased
virus titers, we next studied the effect of CK2β gene silenc-
ing on the initial step of the viral replication cycle: virus
entry. We transfected cells with either control or CK2β
siRNA for 48 h. Cells were then inoculated with a high
dose of virus (MOI = 50), incubated at 4°C for 30 min to
block virus entry while binding to the cell surface, and
incubated at 37°C for 30 min to allow virus entry. The cell
membranes were then stained with an antibody specific
for epidermal growth factor receptor (EGFR) and exam-
ined by confocal microscopy. Virus entry was slowed in
control siRNA-transfected cells but not in CK2β siRNA-
transfected cells, where they had accumulated at the
nuclear membrane (predominantly) and in the nucleus
30 min after temperature shift (Figure 4). Although most
viruses localized at the nuclear membrane of control
siRNA-transfected cells, significantly less viral antigen was
detected within the nucleus, and a large proportion of the
virus population still remained in the cytoplasm and at
the cell membrane (small fraction) (Figure 4). Therefore,
internalization and nuclear import of virus are substan-
tially greater when CK2β protein is absent or reduced.
Inhibition of CK2β expression increases viral protein 
quantity
We next examined whether CK2β gene silencing affects
viral protein synthesis. Cells were transfected with either
control or CK2β siRNA for 48 h, inoculated (MOI = 1) for
9 h or 24 h, and lysed for Western blot analysis. Total
amount of viral protein was detected by using an antibody
specific for IVA of the H1N1 subtype. As NP was the most
heavily expressed of the viral proteins, we quantified the
NP bands. The value obtained at 9 h p.i from cells trans-
fected with control siRNA was assigned a value of 100%.
NP production increased in both control and CK2β
siRNA-transfected cells between 9 h and 24 h p.i. (Figure
5a).
However, a substantially larger amount of viral NP pro-
tein was synthesized in CK2β siRNA-transfected cells than
in control-transfected cells at both time points (Figure
5a). While the expression of a late viral protein (matrix
protein, M1) differed only slightly at 9 h p.i. between cells
transfected with CK2β and control siRNA, M1 expression
was higher in CK2β siRNA-transfected cells than in con-
trol-transfected cells at 24 h p.i. (Figure 5a).
To confirm that cells transfected with control siRNA and
with CK2β siRNA differed in their viral protein content,
we measured expression of NP protein in transfected cells
at 24 h p.i. (MOI = 1) by FACS. Markedly more NP was
produced in cells transfected with CK2β siRNA than in
control siRNA-transfected cells (Figure 5b). 64% of the
cell population transfected with CK2β siRNA expressed
NP, whereas only 38% of the control siRNA-transfected
cells were NP+ (Figure 5b). This finding supports the
results of our Western blot analysis and shows higher pro-
duction of viral NP protein in CK2β siRNA-transfected
cells.
Inhibition of CK2β expression does not affect nuclear RNP 
export
Next, we investigated the contribution of CK2β to the
intracellular localization of the viral RNP complexes. Cells
were transfected with either control or CK2β siRNA for 48
h and then inoculated (MOI = 1) for 6 h and 8 h, the time
points at which optimal nuclear export of RNP usually
occurs [29,32,42]. Viral RNP complexes were stained with
an anti-NP antibody, and CK2β protein was stained with
anti-CK2β antibody. Confocal microscopy demonstrated
a reduced amount of CK2β protein at 6 h and 8 h p.i in
cells transfected with CK2β siRNA. In cells transfected
with control siRNA, the majority of CK2β was found in
the cytoplasm (Figure 6). At 6 h p.i. in cells transfected
with CK2β siRNA, the viral RNP complexes were localized
predominantly in the nucleus, with a small fraction in the
cytoplasm. However, there was no substantial difference
in nuclear RNP export in cells transfected with CK2β and
control siRNA. Further, at 8 h p.i. viral RNP complexes
were distributed in both the cytoplasm and the nuclei of
control and CK2β siRNA-transfected cells (Figure 6),
showing that the nuclear-cytoplasmic transport of viral
RNP complexes is not affected by CK2β or by its absence.Page 6 of 15
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siRNA-mediated CK2β silencing accelerates virus entryFigure 4
siRNA-mediated CK2β silencing accelerates virus entry. A549 cells were transfected with either control or CK2β 
siRNA for 48 h. They were then inoculated at an MOI of 50, chilled at 4°C for 30 min, and incubated at 37°C for 30 min. Influ-
enza A virions (red) were detected with a goat anti-IVA (H1N1) polyclonal antibody, and an epidermal growth factor receptor 
(EGFR)-specific mAb (green) was used as a cell membrane marker. Images were taken with a confocal laser scanning micro-
scope at 100× magnification. Blue arrows indicate virus accumulation at the nuclear membrane; yellow arrows indicate virus 
accumulation in the cytoplasm and at the cell membrane.
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siRNA-mediated silencing of CK2β leads to higher viral protein content. (a) A549 cells were transfected with either 
control (white bars) or CK2β (black bars) siRNA. After 48 h, cells were inoculated at an MOI of 1 and incubated for 9 h or 24 
h before Western blot analysis. Viral proteins were detected with a goat anti-IVA (H1N1) polyclonal antibody. Loading was 
controlled with a mAb against β-actin. Bands of viral protein were quantified as a percentage of control values normalized to 
the loading control. Shown are the mean ± SE from 3 independent experiments. (b) Cells were treated as above. The percent-
age of NP-expressing cells was measured at 24 h p.i. by flow cytometry (FACS) using an anti-NP mAb. The experiments were 
performed in duplicate.
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siRNA-mediated CK2β silencing does not affect nuclear RNP export. A549 cells were transfected with either control 
or CK2β siRNA for 48 h, inoculated with virus at an MOI of 1, and incubated for an additional 6 h or 8 h. The RNP complexes 
and CK2β protein were stained with a goat anti-NP antibody (red) and an anti-CK2β mouse monoclonal antibody (green), 
respectively. The nucleus was counterstained with TO-PRO-3 (blue). Intracellular RNP localization was analyzed at the indi-
cated time points by confocal laser scanning microscopy (100× magnification).
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polymerase activity
We used a minigenome (RNP-like) system to evaluate
whether CK2-mediated phosphorylation of PA and NP
influences viral polymerase activity. Cells were transfected
with either control or CK2β siRNA for 48 h and then co-
transfected with the pol I-driven plasmid encoding the
luciferase gene and pol I/pol II-responsive plasmids that
express the viral PB2, PB1, PA, and NP proteins. After
incubation for 24 h, luciferase activity (indicative of viral
polymerase activity) was assayed in cell extracts. Transfec-
tion without the PB1 plasmid revealed negligible back-
ground luciferase expression. Inhibition of CK2β
expression did not substantially influence viral polymer-
ase activity, which was only slightly greater after CK2β
siRNA treatment than after control siRNA treatment (Fig-
ure 7). The results indicate that the CK2β-mediated phos-
phorylation of PA and NP is not required for regulation of
viral polymerase activity.
Discussion
The molecular mechanisms of influenza virus multiplica-
tion and the interactions between viral and cellular gene
products determine host susceptibility to infection and
disease. We have demonstrated that the regulatory β-sub-
unit of the cellular protein kinase CK2 inhibits IVA repli-
cation in A549 human epithelial lung cells. Importantly,
pulmonary cells are among the first to be targeted by res-
piratory-tract pathogens, such as influenza viruses. When
activated by infection, they can participate in lung inflam-
mation by producing various soluble factors, including
cytokines and by recruiting other cells [43].
siRNAs are widely used to study the function of cellular
genes in vitro and in vivo. We found that this tool effi-
ciently diminished CK2β expression in human lung cells
without affecting the expression of CK2α protein. Cellular
CK2β activation (phosphorylation) was upregulated dur-
ing virus binding and internalization but diminished
when virus replication began. Interestingly, inhibition of
CK2β translation increased virus titers, suggesting that
expression of this cellular kinase is inconsistent with
influenza virus replication. It is noteworthy that virus tit-
ers in the absence of CK2β were inversely proportional to
the MOI used for inoculation (i.e., the lower the MOI, the
higher the titer); titers showed the greatest increase in cells
inoculated at an MOI of 0.001. At this low MOI, the mul-
tiple replication cycles are required to infect the entire cell
population leading to stronger differences in virus titers.
Prevention of CK2β phosphorylation with a CK2 inhibi-
tor also resulted in increased virus titers. In contrast, stim-
ulation of CK2β with polyamine reduced virus titers,
strengthening the evidence that CK2β activation nega-
tively influences virus replication. This finding will facili-
tate further studies to understand the role of CK2β in viral
biology. We hypothesize that the absence of CK2β reduces
the activity of the CK2α subunit, thereby wholly or par-
tially inactivating the heterotetrameric holoenzyme and
providing a viral replication advantage. Our findings are
compatible with a model in which influenza viruses have
acquired the ability to exploit or impede host cell
responses to support viral propagation. Several host fac-
tors other than CK2β have also been shown to possess
anti-influenza virus activity. For example, inhibition of
JNK signaling reportedly increases cellular virus yields
[44].
Moreover, Mx1-induced expression of type I interferons
efficiently protects mice against highly pathogenic H5N1
influenza virus by inhibiting viral polymerase activity,
thereby reducing virus titers in the lung and liver [45].
Thus, to replicate optimally within the infected host,
influenza viruses may employ "virus-supportive" cellular
gene products while concomitantly suppressing the
expression of genes that exert an antiviral effect.
Biochemical and genetic evidence indicates that CK2 par-
ticipates in the maintenance of cell viability and plays a
global anti-apoptotic role [2,46]. Treatment of Jurkat cells
with a specific CK2 inhibitor induces apoptosis [47]. The
anti-apoptotic effect of CK2 is at least partially mediated
by upregulation of the Akt/PKB pathway [48]. Early stud-
ies demonstrated that overexpression of the anti-apop-
totic protein Bcl-2 impairs influenza virus replication and
is associated with a mis-glycosylation of the viral surface
protein hemagglutinin [49]. Another study showed that
when activation of caspase 3 (a major apoptosis effector)
is blocked, export of nuclear RNP is retarded and virus tit-
ers are reduced [50]. These observations indicate that
induction of apoptosis plays a predominantly antiviral
role but can also support influenza virus replication. Thus,
the expression of CK2 protein kinase may prevent virus
propagation by controlling activation of apoptotic path-
ways and thereby reducing virus titers. On the other hand,
previous studies showed that CK2α activity is essential for
influenza virus budding in MDCK cells [51], although the
direct effect on virus titers was not reported. Hence, it
remains to be determined why the α and β subunits of
CK2 appear to have contradictory effects on the replica-
tion of influenza virus, although these discrepancies may
reflect the different cell lines used in the studies.
Export of viral RNPs from the nucleus is a key step in the
influenza virus infectious cycle. Inhibition of CK2β
expression did not affect the nuclear export of viral RNP
complexes at 6 h and 8 h p.i.; thus, nuclear RNP export
does not appear to be responsible for the increase in virus
titers. Instead, influenza virus interacts with and employs
other host factors, such as ERK [29,32], CRM1 [52], and
caspase 3 [50] to accomplish the process of nuclear RNPPage 10 of 15
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induced ERK activation is not affected in either presence
or absence of CK2β (data not shown). In contrast, Bcl-2
appears to be involved in negatively regulating this mech-
anism: in cells expressing Bcl-2 the viral RNP complexes
accumulate around the nuclear membrane, whereas they
are distributed throughout the cytoplasm in control cells
[53]. We also determined the effect of CK2β silencing on
viral polymerase activity in an RNP-like construct.
Although PA and NP are the 2 known phosphoproteins
[33,36,54] in the RNP complexes and are predicted to
possess CK2 phosphorylation sites (NetPhosK 1.0) [55],
presence or absence of the CK2β protein did not affect
viral polymerase activity in this system. Hence, CK2-medi-
ated phosphorylation does not appear to be essential for
viral polymerase activity.
Many viruses use receptor-mediated endocytosis to enter
a target cell [56,57]. Activation of cellular gene products
such as PKCβII and phosphatidylinositol-3-kinase are
suggested to be involved in this process [30,58]. PKCβII
plays a role in both influenza virus entry and EGFR traf-
ficking and degradation. In cells lacking functional PKC-
βII, viral RNP complexes and EGFR were trapped in late
endosomal compartments [30]. In contrast, in cells lack-
ing CK2β protein, a very early step in virus uptake from
the cell membrane into the nucleus was substantially
enhanced. Our immunofluorescence analysis revealed
enhanced virus internalization and accelerated virus
transport from the cytoplasm to the nucleus in cells with
reduced CK2β expression. CK2β gene silencing appeared
to promote influenza virus entry by reducing the inhibi-
tory effect of CK2β. However, further analysis is required
to fully decipher how and at what level CK2β inhibits this
early stage of viral replication.
Reduced or absent CK2β expression substantially
enhanced the cellular viral protein content, suggesting
that CK2β may interfere with viral protein synthesis at the
molecular level, e.g., replication (viral RNA ↔ cRNA),
transcription (cRNA → mRNA), or translation. On the
other hand, a considerably greater quantity of viral NP
was detected at 24 h p.i. than at 9 h p.i., indicating the pro-
gressive spread of infection during that time. We hypoth-
esize that while the viral protein synthesis rate per cell
remains constant, loss of the CK2β protein seems to
increase the susceptibility of A549 cells to influenza virus
infection in the whole cell population. However, further
investigation is needed to determine how CK2β absence
increases cellular viral protein and why this increase does
not significantly affect viral polymerase activity. The effect
of CK2β gene silencing on accumulation of viral RNA,
cRNA, and mRNA in infected cells should be examined in
more detail. Overall, siRNA-mediated CK2β gene silenc-
ing appears to increase cell susceptibility to influenza
virus infection resulting in accelerated virus entry process
and larger viral protein quantity, and these effects in turn
contribute to higher virus titers. However, the molecular
mechanisms remain to be elucidated.
Conclusion
Our results are the first to demonstrate a functional link
between the CK2β protein and regulation of IVA replica-
tion. In contrast to virus-induced upregulation of many
cellular kinases, IVA appears to constrain CK2β activation
during viral replication. We found that CK2β gene silenc-
ing significantly increases virus titers in A549 cells,
explaining the advantage of viral inhibition of CK2β.
Treatment of cells with a specific CK2 inhibitor also
siRNA-mediated CK2β gene silencing does not influence viral polymerase ctivityFigur  7
siRNA-mediated CK2β gene silencing does not influ-
ence viral polymerase activity. Polymerase activity was 
assayed in a minigenome system, using a viral UTR-driven 
luciferase reporter gene. A549 cells were transfected with 
either control or CK2β siRNA for 48 h, then co-transfected 
with plasmids containing the PB2, PB1, PA, and NP genes plus 
a luciferase reporter plasmid. Cells not transfected with the 
PB1 plasmid were used as negative controls. After 24 h, 
polymerase (luciferase) activity was assayed in cell extracts. 
Results represent the mean ± SE of 3 independent experi-
ments.Page 11 of 15
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reduced virus titers, suggesting that CK2β activation nega-
tively affects virus replication. CK2β gene silencing
impaired neither nuclear export of viral RNP complexes
nor viral polymerase activity. However, it appears to
increase cell susceptibility to influenza virus infection and
thereby accelerates virus entry process and boosts the total
viral protein content. siRNA-mediated CK2β gene silenc-
ing may be useful in improving the yield of vaccine-strain
influenza virus. Clinically, it may be possible in the future
to introduce a construct expressing a constitutively active
CK2β into influenza-infected hosts as a therapeutic inter-
vention.
Materials and methods
Cells, virus, and infection
The human epithelial lung cell line A549 was purchased
from the American Type Culture Collection (Rockville,
MD) and was cultured in FK12 medium containing 10%
(v/v) fetal bovine serum (FBS) and 1% (v/v) antibiotics
(penicillin/streptomycin). Madin-Darby canine kidney
(MDCK) cells were maintained in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 10% (v/v)
fetal calf serum (FCS) and 1% (v/v) antibiotics (penicil-
lin/streptomycin). All cells were cultivated at 37°C in a
humidified atmosphere containing 5% CO2. The H1N1-
subtype human influenza virus A/Puerto Rico/8/34 (PR/
8) was generated by 8-plasmid reverse genetics [59] and
used at the indicated multiplicity of infection (MOI; deter-
mined in MDCK cells) in the presence of TPCK trypsin
(1:6000).
Virus titration (plaque assay)
Confluent monolayers of MDCK cells in 35-mm dishes
were inoculated with 10-fold dilutions of PR/8 influenza
virus in DMEM with 3% bovine serum albumin (BSA)
and antibiotics and incubated at 37°C for 1 h. The inocu-
lum was removed, and cells were washed with PBS and
overlaid with 2-fold DMEM containing 1.8% bacto-agar,
0.2% BSA, and 2 μg/ml TPCK trypsin. After 3 days of incu-
bation at 37°C, cells were stained with 0.1% crystal violet
in 10% formaldehyde solution and the plaques were
counted.
Cell treatment with CK2 inhibitor and activator
To determine the effect of CK2 inhibition, confluent mon-
olayers of A549 cells in 35-mm dishes were treated with 5
μM 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimida-
zole (DMAT; Calbiochem, San Diego, CA) or with solvent
(DMSO) (Sigma-Aldrich, St. Louis, MO) 1 h prior to infec-
tion. To determine the effect of CK2β activation, cells were
treated with 300 μM spermine (Sigma-Aldrich) or with
H2O 1 h prior to infection. Cells were then inoculated at
MOI = 5 in the presence of DMAT or DMSO. Virus-con-
taining supernatants were harvested 24 h post-infection
(p.i.) and virus titers were determined by plaque assay.
Transient siRNA transfection
Human CK2β siRNA (Santa Cruz Biotechnology, Santa
Cruz, CA) is a pool of 3 target-specific 20- to 25-nt siRNAs
designed to silence CK2β gene expression in human cells.
A549 cells (grown in 35-mm dishes) were transfected with
siRNA duplex (1 μg) by using Lipofectamine 2000 (Invit-
rogen, New Brunswick, NJ). The control siRNA (Santa
Cruz Biotechnology) is a nontargeting 20- to 25-nt siRNA
that does not cause specific degradation of any known cel-
lular mRNA. Cells were transfected for 48 h, washed with
FK12 medium without supplements, then inoculate at the
indicated MOIs and incubated for different time periods,
depending on the purpose of the experiment. Transfection
efficiency monitored by fluorescein-conjugated control
siRNA (Santa Cruz Biotechnology) varied up to 85%
(flow cytometry analysis) according to the maximum pro-
tein level reduction.
Cell proliferation assay
A549 cells were grown in 96-well dishes and transfected
with 1 μg of CK2β siRNA or control siRNA for 24 h, 48 h,
or 72 h at 37°C, 5% CO2. The cell medium was then
replaced with fresh medium. After further incubation for
1 h, the medium was replaced with 200 μl of FK12
medium containing 10% (v/v) FBS and tetrazolium bro-
mide (MTT; 175 μg mL-1, Sigma-Aldrich). After 90 min,
the incubation medium was replaced with PBS/4% para-
formaldehyde (PFA), and cells were fixed for 30 min at
room temperature (RT). Cells were air dried and, after
addition of isopropanol (150 μL/well), plates were vigor-
ously agitated for 10 min. The plates were photometrically
analyzed at 550 nm in an enzyme-linked immunosorbent
assay reader (Bio-Rad Microplate Reader, Model 680). Six-
teen samples from each group were measured, and the
mean and standard error was calculated. Cell morphology
was analyzed by confocal laser scanning microscopy after
transfection with either siRNA.
Western blot analysis
Cell lysate was cleared by centrifugation, and total protein
concentration was determined by the Bradford assay
before separation by SDS-PAGE. A rabbit polyclonal anti-
body that detects phosphorylated CK2β (P-S209) (1:200;
abcam, Cambridge, MA) was used to determine CK2β
activity. Expression of CK2α and CK2β were detected with
anti-CK2α (1:200; Calbiochem) and anti-CK2β (1:500;
Calbiochem) mouse monoclonal antibody, respectively.
Anti-β-actin mouse monoclonal antibody (1:500; Santa
Cruz Biotechnology) was used to detect β-actin expression
as a protein-loading control. Proteins recognized by mAbs
were further analyzed with horseradish peroxidase-conju-
gated, species-specific secondary antibodies (1:2000; Jack-Page 12 of 15
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enhanced chemiluminescence reaction (Amersham Bio-
sciences, Piscataway, NJ). Specific bands were quantified
by using the PC-BAS software package (Fuji, Kanagawa,
Japan). To detect synthesis of viral proteins, cells were
incubated with a goat anti-IVA (H1N1) polyclonal anti-
body (1:500; Biodesign International, Saco, ME).
To detect ERK activation, cells were transfected with either
control or CK2β siRNA for 48 h and were then infected at
an MOI of 5 and further incubated for 4, 6, or 8 h. After
Western blot analysis, ERK activation was measured with
a mAb specific for phosphorylated ERK (1:500; Santa
Cruz Biotechnology). ERK2 (1:500; Santa Cruz Biotech-
nology) served as a protein loading control.
FACS analysis
After 48 h of transfection with either siRNA, cells were
infected at MOI = 1 and incubated for 24 h. Cells were
detached with trypsin, fixed in PBS/4% PFA, permeabi-
lized with 1% Triton X-100, and incubated with FITC-con-
jugated mouse anti-NP mAb (clone IA52, 1:500; Argene
Inc) in PBS/3% BSA for 30 min on ice. The percentage of
NP-expressing cells was determined by FACS analysis
using (FACSCalibur, BD Biosciences, Rockville, MD).
Indirect immunofluorescence assay and confocal laser 
scanning microscopy
A549 cells grown on collagen-coated glass coverslips (BD,
Franklin Lakes, NJ) were transfected with either control or
CK2β siRNA for 48 h, then infected at MOI = 1 and incu-
bated further for 6 h and 8 h. Cells were washed with PBS
at the indicated time points p.i. and fixed with 4% PFA in
PBS for 30 min at room temperature or overnight at 4°C.
Cells were permeabilized with 1% Triton X-100 in PBS for
10 min and incubated with a goat anti-NP antibody, clone
G150 (1:100; St Jude Children's Research Hospital) and
anti-CK2β mouse monoclonal antibody (1:100; Calbio-
chem) in PBS/3% BSA for 1 h for analysis of the nuclear
export of RNP complexes and the amount of expressed
CK2β protein. The AlexaFluor488-conjugated goat anti-
mouse antibody and AlexaFluor594-conjugated donkey
anti-goat antibody (1:200; Molecular Probes, Invitrogen,
Carlsbad, CA) were used as secondary antibodies. Cells
were washed with PBS and then with double-distilled
water and mounted with para-phenylene diamine
(Sigma-Aldrich) containing 500 nM TO-PRO-3 (Molecu-
lar Probes, Invitrogen) for nuclear staining. Fluorescence
was visualized with a confocal laser scanning microscope
(LSM 510 META, Carl Zeiss, Germany).
To study virus entry, cells were infected at a MOI = 50,
chilled at 4°C for 30 min, and incubated at 37°C for 30
min. Cells were permeabilized, fixed, and incubated with
a combination of goat anti-IVA (H1N1) polyclonal anti-
body (1:100) (Biodesign International) and mouse anti-
epidermal growth factor receptor (EGFR) mAb (1:100;
Santa Cruz Biotechnology). Alexa594-conjugated donkey
anti-goat and AlexaFluor488-conjugatedgoat anti-mouse
antibodies (Molecular Probes) were used as secondary
antibodies.
Luciferase assays
Subconfluent monolayers of A549 cells (7.5 × 105 cells in
35-mm dishes) were transfected with CK2β siRNA or con-
trol siRNA for 48 h. Cells were then transfected with 2 μg
of luciferase reporter plasmid (enhanced green fluores-
cent protein (EGFP) open reading frame in pHW72-EGFP
substituted with the luciferase gene[60]) and a mixture of
the PB2 (1 μg), PB1 (1 μg), PA (1 μg), and NP (2 μg) plas-
mids of A/Puerto-Rico/8/34 (H1N1) virus. After 24 h, cell
extracts were prepared in 500 μL of lysis buffer, and luci-
ferase levels were assayed with a luciferase assay reagent
kit (Promega, Madison, WI) and BD Monolight 3010
luminometer (BD Biosciences).
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